Code intelligence

FDA-NDA021131 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA021131.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

no upcoming deadlines

FDA Approval: ZYVOX (LINEZOLID) — Type 3 - New Dosage Form

Policy FDA-NDA021131 · Infectious Disease

High

ZYVOX (Linezolid) is an injectable drug likely to receive a J-code assignment for billing. It will be billed under Part B, and potential ASP+6% payment may apply due to its injectable nature.